Match Document Document Title
5789150 Process for the sterilization of biological compositions using UVA1 irradiation  
An improvement in a process for inactivating extracellular and intracellular viruses in a platelet containing composition is presented. The improvement in the process comprises adding a sensitizer...
5788963 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy  
Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human...
5785964 Three-dimensional genetically engineered cell and tissue culture system  
The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance...
5786213 Inhibition of endogenous gastrin expression for treatment of colorectal cancer  
The present invention discloses is for the treatment of colon cancer. The expression of gastrin by colon cancers is inhibited by the use of antisense gastrin expression. Methods are disclosed for...
5785965 VEGF gene transfer into endothelial cells for vascular prosthesis  
Endothelial cells derived from subcutaneous adipose tissue are genetically modified to express the endothelial cell-specific angiogenic factor VEGF. The modified cells are sodded onto a vascular...
5780447 Recombinant adeno-associated viral vectors  
The present invention provides a vector comprising an enhancer element and a nuclear matrix association region inserted between an inverted terminal repeat of adeno-associated virus. The vector can...
5766585 Systemic gene treatment of connective tissue diseases with IRAP-1  
The present invention relates to methods of therapeutic or prophylactic treatment of connective tissue diseases by systemic or local delivery of a nucleic acid sequence to a mammalian host....
5767364 Endo-1,4-beta-D-glucanase  
A sequence encoding an enzyme having a xyloglucan-specific endo-(1-4)-beta-D-glucanase activity, and functional equivalents thereof, is disclosed. Also disclosed are vectors comprising such...
5762926 Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system  
Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. The modified donor cells...
5763416 Gene transfer into bone cells and tissues  
Disclosed are methods, compositions and devices for use in transferring nucleic acids into bone cells in situ. The transfer of an osteotropic gene into bone progenitor cells is described, which...
5762927 Thymus tolerance in primates  
Disclosed is a method of inhibiting a rejection response by a primate to a transplanted organ. One exposes the primate to a mutant diphtheria toxin linked to anti-CD3 antibody so as to largely...
5759535 Immunotherapeutic strategies for the treatment of cancer  
The present invention is directed to a method for the treatment of neoplastic disease comprising administering to a mammal having a tumor a cellular immunogen comprising an allogeneic population of...
5759765 Human liver epithelial cell lines  
Immortalized cell lines derived from normal adult human liver are described which express phenotypic characteristics of normal adult liver epithelial cells. The invention further provides methods...
5759536 Use of fas ligand to supress T-lymphocyte-mediated immune responses  
A method for inhibiting T-lymphocyte-mediated immune responses, including those directed against autologous and/or heterologous tissues, e.g., by a recipient mammal of a transplanted tissue, said...
5753491 Use of neuro-derived fetal cell lines for transplantation therapy  
The present invention generally relates to methods for treating a host by implanting genetically unrelated cells in the host. More particularly, the present invention provides human fetal...
5753221 Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions  
The invention relates to compositions of erythrocytes that have been modified following hypotonic lysis and resealing by addition of 2',3'-dideoxycytidine-5'-triphosphate (ddCTP) or...
5750102 Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis  
The present invention relates to anti-tumor vaccines comprising at least one type of tumor cell into each of which at least two genes encoding MHC proteins of different haplotypes have been...
5741486 Safe vectors for gene therapy  
The present invention provides retroviral vectors comprising direct repeats flanking a sequence that is desired to be deleted upon reverse transcription in a host cell. In a preferred embodiment...
5739006 Process of feeding juvenile fish with astaxanthin-containing zooplankton  
The present invention relates to astaxanthin-containing zooplankton such as Brachionus pricatilis obtained by culturing, a method for culturing the zooplankton in a liquid containing astaxanthin...
5736387 Envelope fusion vectors for use in gene delivery  
The invention provides retroviral vectors which can be used for directing gene delivery to a specific sub-population of mammalian cells. The vectors comprise chimeric targeting proteins which...
5733543 Introduction of HIV-protective genes into cells by particle-mediated gene transfer  
Foreign genes may be stably introduced into T cells, monocytes, macrophages, dendrites, and hematopoietic stem cells by particle-mediated gene transfer. Introduction of an HIV protective gene into...
5716821 Prevention and treatment of respiratory tract disease  
Recombinant methods for recovering wildtype or engineered negative stranded, non-segmented RNA virus genomes containing non-coding 3' and 5' regions (e.g. leader or trailer regions) surrounding...
5710037 Retroviral vector particles  
A retroviral vector which includes a nucleic acid sequence encoding a retroviral envelope. The nucleic acid sequence encoding a retroviral envelope includes a first nucleic acid sequence encoding a...
5707864 Nucleic acids encoding mutated human immunodeficiency virus matrix proteins  
Nucleic acid constructs encoding mutated human immunodeficiency virus matrix proteins are described. The mutated proteins lower the incorporation of envelope polypeptides in viral particles,...
5707865 Retroviral vectors for expression in embryonic cells  
Retroviral plasmid vectors which include an enhancer region obtained from a virus selected from the group consisting of Myeloproliferative Sarcoma Virus and polyoma virus, and a primer binding site...
5705151 Gene therapy for T cell regulation  
The present invention provides a nucleic acid-based therapeutic composition to treat an animal with disease by controlling the activity of effector cells, including T cells, macrophages, monocytes...
5702702 Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer  
The invention provides a modified human cytotoxic T cell line, which is characterized by dual activity in vitro and in vivo against malignant cells and virus-infected cells. Also provided are...
5700690 Compositions and methods for inhibiting fibrogenesis  
Vectors, or naked DNA, containing a promoter for an FSP1 gene and a downstream gene capable of attenuating fibroblasts and their function are provided. Methods of using these vectors to inhibit...
5698443 Tissue specific viral vectors  
Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only...
5690927 Use of neuro-glial fetal cell lines for transplantation therapy  
Human fetal neuro-derived cell lines are implanted into host tissues. The methods allow for treatment of a variety of neurological disorders and other diseases. A preferred cell line is SVG.
5690926 Pluripotential embryonic cells and methods of making same  
The claimed invention is directed towards non-murine pluripotential cells that have the ability to be passaged in vitro for at least 20 passages and which differentiate in culture into a variety of...
5688773 Method of selectively destroying neoplastic cells  
A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene...
5681562 Lymphokine gene therapy of cancer  
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to...
5674486 Cancer immunotherapy with carrier cells  
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to...
5672493 De novo induction of cells exhibiting characteristics of macrophages utilizing feline sarcoma virus  
This invention relates to cells that demonstrate characteristics of tissue macrophages (CCTM), including all substances obtained therefrom, such CCTM are induced from human fibroblasts (HF) by the...
5670148 Combined cellular and immunosuppressive therapies  
Novel regimens are provided for administering foreign genetically modified allogeneic cells to a host by combining the administration of the cells with a reduced regimen of an immunosuppressive...
5665350 Cell cycle dependent transplantation and ex vivo gene therapy  
Methods for the enhancement of bone marrow stem cell engraftment are provided for use in transplantation therapy and ex vivo gene therapy of a mammal. The methods involve the transplantation of...
5658565 Inducible nitric oxide synthase gene for treatment of disease  
The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed...
5656605 Device to promote drug-induced nerve regeneration  
The invention relates generally to a system for promoting regeneration of a damaged nerve. In particular, the invention comprises: (1) a guide tube constructed to be attached to the damaged nerve;...
5656475 Use of lymphocytes transformed with herpesvirus saimiri in a process for replicating viruses of the HIV type which cause immune deficiency  
A process is disclosed for replicating viruses of the HIV type which cause immune deficiency, in which process lymphocytes are employed which have been transformed with herpesvirus saimiri.
5656267 Implantable cells that alleviate chronic pain in humans  
This invention provides a method of alleviating chronic pain in humans. Viable, implantable cells are selected which release neuroactive substances that reduce chronic pain. The cells are cultured...
5651965 Bacillus thuringiensis toxins and genes active against nematodes  
The invention concerns novel isolates of Bacillus thuringiensis (B.t.) which contain a toxin(s) which is active against nematodes. This B.t. toxin(s) or B.t. isolate(s) can be used to treat animals...
5652130 Retroviral vectors expressing tumor necrosis factor (TNF)  
A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering...
5643890 Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases  
A method of inhibiting proliferation of immortal cells or cells that express telomerase is disclosed. The method includes introduction of synthetic oligonucleotides which mimic telomere motifs....
5637483 Irradiated tumor cell vaccine engineered to express GM-CSF  
A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The...
5635399 Retroviral vectors expressing cytokines  
A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering...
5629469 Thiol protease inhibitor  
A novel thiol protease inhibitor peptide is isolated from Diabrotica virgifera designated virgiferin. The DNA encoding virgiferin and modified virgiferin peptides are claimed. These sequences maybe...
5628995 Control of Ostrinia  
A method to combat or control Ostrinia nubilalis by contacting such insects with a CryIB protein or a combination of a CryIB protein and a CryIAb or CryIAc protein.
5628781 Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves  
Implant materials having porosity are provided by the present invention. Methods for treating a synthetic or naturally occurring implant, such as a vascular graft, intended for implantation in a...
5626850 Non-shedding live herpesvirus vaccine  
The present invention is concerned with a genetically modified live herpesvirus vaccine of which the live herpesviruses are not shed into the environment by a vaccinated animal. This can he...